HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

cilazaprilat

InChIKey: UVAUYSRYXACKSC-ULQDDVLXSA-N

Also Known As:

Ro 31-3113; Ro 313113; cilazaprilat anhydrous

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - Cilazapril: 287
      - cilazaprilat: 5

Experts

1.	Echizen, Hirotoshi: 1 article (12/2014)
2.	Ogawa, Ryuichi: 1 article (12/2014)
3.	Stachnik, Joan M: 1 article (12/2014)

Related Diseases

1.	Hypoxia (Hypoxemia) 02/16/1999 - "The present study was designed to examine whether an ACE inhibitor, cilazaprilat, directly protects cardiac myocytes against hypoxia/reoxygenation (H/R) injury. " 02/16/1999 - "Cilazaprilat significantly enhanced bradykinin production in the culture media of myocytes after 5.5 hours of hypoxia but not in that of nonmyocytes. " 02/16/1999 - "In addition, cilazaprilat markedly enhanced the cGMP content in myocytes during hypoxia, and this augmentation in cGMP could be blunted by L-NMMA and methylene blue but not by aminoguanidine. "
2.	Coronary Occlusion 06/01/1998 - "The ACE inhibitor cilazaprilat was administered into the coronary artery 10 minutes before coronary occlusion, and infusion was continued until 1 hour after reperfusion. "
3.	Reperfusion Injury 12/01/1997 - "Since a beneficial effect of ACE-inhibition on reperfusion injury has been reported, we investigated the impact of cilazaprilat on PMN dependent reperfusion injury in isolated guinea pig hearts. "
4.	Ischemia 06/01/1998 - "Although there were no significant differences in collateral flow during ischemia, infarct size in the cilazaprilat group was smaller than that in the control group (15.1+/-3.0% versus 46.7+/-4.2% of the area at risk, P<0.0001). "
5.	Infarction (Infarctions) 06/01/1998 - "Although there were no significant differences in collateral flow during ischemia, infarct size in the cilazaprilat group was smaller than that in the control group (15.1+/-3.0% versus 46.7+/-4.2% of the area at risk, P<0.0001). " 06/01/1998 - "The infarct size-limiting effect of cilazaprilat was partially reduced by either N(G)-nitro-L-arginine methyl ester (an inhibitor of NO synthase) or iberiotoxin (a blocker of Ca2+-activated K+ channels) and was abolished by N(G)-nitro-L-arginine methyl ester plus iberiotoxin. "

Related Drugs and Biologics

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.	Enalaprilat (Vasotec)
3.	Bradykinin
4.	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)
5.	Perindopril
6.	Milrinone (Primacor)
7.	NG-Nitroarginine Methyl Ester (L-NAME)
8.	omega-N-Methylarginine (NG Monomethyl L Arginine)
9.	Nitric Oxide Synthase (NO Synthase)
10.	Enoximone

Related Therapies and Procedures

1.	Oral Administration